Reports on MS Treatment Market Show Growing Shift to Oral Therapies

The multiple sclerosis (MS) market shifted during 2016, with oral disease-modifying therapies (DMTs) capturing a greater share and Sanofi-Genzyme’s Aubagio (teriflunomide) being poised for growth, according to a press release from Spherix Global Insights. The conclusions were included in the company’s “RealTime Dynamix: Multiple Sclerosis,” a quarterly report based…

Effectiveness and Safety of DMDs Top Patient Concerns with These Therapies, Survey Says

In general, patients with multiple sclerosis (MS) choose their disease-modifying drug (DMD) treatment based on considerations of effectiveness and potential side effects. But the weight they assign to these considerations can differ widely, making it important they are part of treatment decisions, especially regarding DMDs. These findings are in the report, “Identification and…

#CMSC16 – Study of PPMS Patient Characteristics Highlights Need for More Information

People with primary progressive multiple sclerosis (PPMS) are usually older and more disabled than those with relapsing-remitting MS, researchers at Washington University reported. The team is studying demographic and clinical characteristics of PPMS patients enrolled in the NARCOMS registry, to better understand their unmet needs and possibly improve research into potential treatments. The study, “…

New MS Survey Looks into Patients’ Appraisal of Risks, Benefits When Choosing Therapies

A large-scale online survey, funded by the National Multiple Sclerosis Society  and developed by researchers, is investigating how multiple sclerosis (MS) patients perceive and evaluate the risks and benefits of available therapies. Investigators encourage MS patients to participate in the survey, titled “Multiple Sclerosis Risk Tolerance,” which can be…

Biogen’s ‘1MSg Campaign’ Encourages MS Patients to Better Manage Their Disease, Engage with Specialists

Biogen is launching an initiative developed with the assistance of clinical experts — the 1MSg campaign — to educate and encourage multiple sclerosis (MS) patients to make disease management decisions that are well-informed and based on the latest scientific research. The campaign’s motto is “Take control, known your choices,” and one of its main…

MS Society Supports 2 Projects Advancing MS Care, Services

The United Kingdom based Multiple Sclerosis Society (MS Society) recently announced £1.98 million in grants to new MS research projects in different disease-related areas. A panel of experts carefully selected 16 projects to be funded through the MS Society’s 2015 grant round, totaling £1,979,879. All selected projects fulfill the requirements of…